Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Waters Expands CORTECS Analytical Column Portfolio

Waters Corporation
Posted on: 10 Nov 16

Waters Corporation (NYSE:WAT) today expanded its CORTECS® Columns product line with the introduction of two new chemistries: Waters® CORTECS T3 and CORTECS Shield RP18. These new CORTECS column chemistries allow scientists to obtain more information per analysis and reduce the cost of analyzing complex samples such as biomarkers, natural products, counterfeit cosmetics, synthetic cannabinoids, veterinary drugs, drinking water, and vitamins.

This Smart News Release features multimedia. View the full release here:

Waters Corporation introduces two new column chemistries: Waters® CORTECS T3 and CORTECS Shield RP18 allowing scientists to obtain more information per analysis and reduce the cost of analyzing complex samples. (Photo: Business Wire)

“Today’s scientists want more tools for improving the resolution, speed, selectivity, and sensitivity of their UPLC, UHPLC, and HPLC separations,” said Doug McCabe, Director of Product Management - Consumables Group. “CORTECS Columns deliver the batch-to-batch reproducibility, robustness, and quality that customers have come to expect from Waters.”

When used with an ultra-low dispersion ACQUITY UPLC® instrument platform, the CORTECS UPLC 1.6 micron particle columns are designed to deliver approximately 40% greater increase in separations efficiency when compared to fully porous particles of an equivalent particle size. The highly-efficient CORTECS 2.7 micron particle columns are for use on both the ACQUITY Arc™ UHPLC system and the Waters Alliance® HPLC system and operate at lower backpressures allowing for the use of longer column lengths to improve resolution or shorten analysis times and increase throughput.

The CORTECS T3 and CORTECS Shield RP18 chemistries compliment the currently available CORTECS C18+, C18, C8, Phenyl, and HILIC chemistries. All CORTECS chemistries are fully scalable between the 1.6 micron and 2.7 micron particle sizes. The CORTECS T3 and CORTECS Shield RP18 chemistries are offered in 48 unique column configurations and are immediately available for shipping worldwide.

It’s All in the Chemistry

With different particle characteristics and innovative charged surface modifications, CORTECS Columns are suitable for use in a wide variety of applications.

CORTECS T3 columns provide balanced retention for polar and non-polar molecules when run under reversed-phase LC conditions. The increased pore diameter (120Å vs. 90Å) along with the lower C18 ligand density and proprietary end capping enables the CORTECS T3 chemistry to operate in 100% aqueous mobile phase without the fear of the phase dewetting.

Shield RP18 columns utilize an embedded carbamate functional group into the alkyl ligand which provides alternative selectivity for basic and polyphenolic compounds when compared to typically bonded C18 phases. The embedded polar carbamate groups act as hydrogen bond acceptors, and provide unique selectivity especially for basic and polyphenolic compounds.

For more information:

About Waters Corporation ( )

Waters Corporation (NYSE:WAT) develops and manufactures advanced analytical and material science technologies for laboratory dependent organizations. For more than 50 years, the company has pioneered a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis systems.

Waters, ACQUITY, ACQUITY UPLC, ACQUITY Arc, Alliance, UltraPerformance LC, UPLC and CORTECS are trademarks of Waters Corporation.

View source version on

Business Wire

Last updated on: 10/11/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.